ALK and ROS1 are prognostic and predictive tumor markers in non-small cell lung carcinoma (NSCLC), which are more often found in lung adenocarcinomas as with other oncogenes such as EGFR, KRAS, or C-MET. Their positivity is 2.6% and 1.3%, respectively, and patients who have mutations in both genes are extremely rare. Here, we report a 61-year-old male diagnosed with acinar adenocarcinoma, who was shown to have both ALK and ROS1 rearrangements but was EGFR-and C-MET mutation-negative. He was treated surgically and received targeted therapy. Our review of the literature revealed that few such cases of concurrent ALK and ROS1 rearrangements have been reported. This information furthers our understanding of the molecular biology underlying NSCLC which will aid the selection of optimal treatment for patients with more than one driver mutation.
第一作者机构：[1]Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China
通讯作者：
通讯机构：[1]Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China[*1]Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang 050011, PR China
推荐引用方式(GB/T 7714)：
Deng Huiyan,Liu Chang,Zhang Guoliang,et al.Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures[J].PATHOLOGY RESEARCH AND PRACTICE.2018,214(12):2103-2105.doi:10.1016/j.prp.2018.09.028.
APA：
Deng, Huiyan,Liu, Chang,Zhang, Guoliang,Wang, Xiaoling&Liu, Yueping.(2018).Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.PATHOLOGY RESEARCH AND PRACTICE,214,(12)
MLA：
Deng, Huiyan,et al."Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures".PATHOLOGY RESEARCH AND PRACTICE 214..12(2018):2103-2105
